AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24188499 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-BFR (high-intensity resistance training with blood flow restriction) during the second 4 weeks
Number of subjects: 20
Study 20947374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (1 or 2.5 mg) plus aspirin (75-150 mg/day)
Number of subjects: 90
Study 20947374 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin (75-150 mg/day)
Number of subjects: 90
Study 20634633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nei-Guan acupressure
Number of subjects: 51
Study 20634633 — intervention group
Group type: COMPARATOR
Intervention: Finger acupressure
Number of subjects: 51
Study 20634633 — intervention group
Group type: COMPARATOR
Intervention: Relief band
Number of subjects: 51
Study 17568349 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-LASIK
Number of subjects: 29
Study 15316750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral docetaxel combined with 500 mg OC144‐093
Number of subjects: 12
Study 15316750 — intervention group
Group type: COMPARATOR
Intervention: 100 mg i.v. docetaxel
Number of subjects: 12
Study 11172188 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of therapy for 12 weeks
Number of subjects: 16
Study 11172188 — intervention group
Group type: COMPARATOR
Intervention: Continuation of therapy
Number of subjects: 16
Study 9641004 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 12
Study 7586104 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining temperature at 34 degrees C without rewarming
Number of subjects: 30
Study 7586104 — intervention group
Group type: COMPARATOR
Intervention: Rewarming to 36-37 degrees C
Number of subjects: 30
Study 2138182 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg single injection, continuous infusion at 5 and 10 micrograms/kg.min)
Number of subjects: 36
Study 2138182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 6777804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 210
Study 6777804 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 210
Study 6777804 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 210
Study 31183369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual locking plates in orthogonal configuration
Number of subjects: 32
Study 31183369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual locking plates in adjacent configuration
Number of subjects: 32
Study 31183369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual locking plates
Number of subjects: 32
Study 31183369 — intervention group
Group type: COMPARATOR
Intervention: Dual locking plates (adjacent and orthogonal) after removal
Number of subjects: 32
Study 31183369 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual plates
Number of subjects: 32
Study 27916746 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1811
Study 27916746 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1811
Study 27701064 — intervention group
Group type: COMPARATOR
Intervention: SMART Recovery (SR) meetings alone
Number of subjects: 189
Study 27701064 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcoming Addictions (OA) and SMART Recovery (OA+SR)
Number of subjects: 189
Study 27701064 — intervention group
Group type: COMPARATOR
Intervention: Both SR and OA
Number of subjects: 189
Study 27701064 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who stopped drinking before joining the trial
Number of subjects: 189
Study 23769325 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved adherence to medication
Number of subjects: 363
Study 22993335 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-interferon α-2b (PEG-IFN) for up to 5 years
Number of subjects: 1256
Study 22993335 — intervention group
Group type: COMPARATOR
Intervention: Observation-alone
Number of subjects: 1256
Study 19543808 — intervention group
Group type: EXPERIMENTAL
Intervention: Heteroscedasticity-adjusted OLS (full model)
Number of subjects: 151
Study 19543808 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAD (short model)
Number of subjects: 151
Study 19543808 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAD (reduced model)
Number of subjects: 151
Study 17522936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic restorative proctocolectomy (LRP)
Number of subjects: 60
Study 17522936 — intervention group
Group type: COMPARATOR
Intervention: Open restorative proctocolectomy (ORP)
Number of subjects: 60
Study 15791380 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor training
Number of subjects: 48
Study 15791380 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychomotor training)
Number of subjects: 48
Study 15791380 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced surgeons
Number of subjects: 48
Study 15791380 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents (group 2)
Number of subjects: 48
Study 15791380 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students (group 3)
Number of subjects: 48
Study 11433751 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour instillation of pirarubicin (THP)
Number of subjects: 79
Study 11433751 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min instillation of pirarubicin (THP)
Number of subjects: 79
Study 11433751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 79
Study 9885751 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser punctal ablation
Number of subjects: 32
Study 9885751 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery punctal occlusion
Number of subjects: 32
Study 8058420 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol administered by metered dose inhaler through a spacer device (Babyhaler)
Number of subjects: 9
Study 8058420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2221865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) taken 1 hour before a meal (BE)
Number of subjects: 28
Study 2221865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) taken with a meal (WI)
Number of subjects: 28
Study 2221865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) taken 1 hour after a meal (AF)
Number of subjects: 28
Study 2221865 — intervention group
Group type: COMPARATOR
Intervention: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 250 ml
Number of subjects: 28
Study 2221865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 450 ml
Number of subjects: 28
Study 657082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (30 mg/kg total dose) given for one six-day course immediately after mastectomy
Number of subjects: 507
Study 657082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 507
Study 657082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (30 mg/kg total dose)
Number of subjects: 507
Study 657082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (30 mg/kg total dose) given 3 weeks after mastectomy
Number of subjects: 507
Study 31791707 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional writing
Number of subjects: 72
Study 31791707 — intervention group
Group type: COMPARATOR
Intervention: Non-emotive control writing task
Number of subjects: 72
Study 31424709 — intervention group
Group type: EXPERIMENTAL
Intervention: HBP-Foam (0.05%)
Number of subjects: 560
Study 31424709 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 560
Study 28207554 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated troponin rise (ITR)
Number of subjects: 312
Study 28207554 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome (ACS)
Number of subjects: 312
Study 28207554 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 312
Study 25621553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuber‐Plant
Number of subjects: 97
Study 25621553 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Plant
Number of subjects: 97
Study 25621553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 97
Study 23945188 — intervention group
Group type: EXPERIMENTAL
Intervention: Vietnamese RUTF (locally developed bar)
Number of subjects: 67
Study 23945188 — intervention group
Group type: COMPARATOR
Intervention: Plumpy'nut® (commercially available peanut-based RUTF paste)
Number of subjects: 67
Study 23945188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RUTFs (Vietnamese RUTF and Plumpy'nut®)
Number of subjects: 67
Study 21305590 — intervention group
Group type: EXPERIMENTAL
Intervention: Staggered furosemide and desmopressin
Number of subjects: 82
Study 21305590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 19826132 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Number of subjects: 2157
Study 19826132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 2157
Study 19826132 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 2157
Study 19826132 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 2157
Study 17086503 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention (workplace assessment, work modifications, and case management)
Number of subjects: 0
Study 17086503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical intervention (physiotherapy based on operant behavioural principles)
Number of subjects: 0
Study 17086503 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention followed by clinical intervention
Number of subjects: 0
Study 17086503 — intervention group
Group type: COMPARATOR
Intervention: Usual care (provided by an occupational physician)
Number of subjects: 0
Study 15483784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (6 g ethyl ester daily for 16 weeks)
Number of subjects: 22
Study 15483784 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (SO) supplementation (6 g ethyl ester daily for 16 weeks)
Number of subjects: 22
Study 11686813 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Crest Complete)
Number of subjects: 47
Study 11686813 — intervention group
Group type: COMPARATOR
Intervention: Powered toothbrush (Braun 3D Plaque Remover)
Number of subjects: 47
Study 11686813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Manual and Powered toothbrush)
Number of subjects: 47
Study 9623428 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 13
Study 9623428 — intervention group
Group type: COMPARATOR
Intervention: Control (pancuronium or gallamine)
Number of subjects: 13
Study 7888537 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (buffered powder for oral solution, total daily doses of 6.6‐10 mg/kg)
Number of subjects: 21198
Study 3184196 — intervention group
Group type: COMPARATOR
Intervention: CVPP (cyclophosphamide, vinblastine, procarbazine, and prednisone) alone for 6 monthly cycles
Number of subjects: 277
Study 3184196 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP plus RT (radiation therapy, 3,000 rad)
Number of subjects: 277
Study 3184196 — intervention group
Group type: COMPARATOR
Intervention: CVPP alone
Number of subjects: 277
Study 3184196 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP plus RT
Number of subjects: 277
Study 3184196 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus CVPP
Number of subjects: 277
Study 4880663 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of tetracycline, divided into 4 doses, daily for 5 days
Number of subjects: 0
Study 4880663 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of tetracycline in a single dose daily for 5 days
Number of subjects: 0
Study 4880663 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1.0 g of tetracycline
Number of subjects: 0
Study 4880663 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin preparations
Number of subjects: 0
Study 31755823 — intervention group
Group type: EXPERIMENTAL
Intervention: RABB (210 kcal)
Number of subjects: 21
Study 31755823 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM (210 kcal)
Number of subjects: 21
Study 31755823 — intervention group
Group type: EXPERIMENTAL
Intervention: MCM (635 kcal)
Number of subjects: 21
Study 31755823 — intervention group
Group type: COMPARATOR
Intervention: NF (0 kcal)
Number of subjects: 21
Study 31200019 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptavidin affinity grids
Number of subjects: 0
Study 31200019 — intervention group
Group type: COMPARATOR
Intervention: Conventional sample preparation methods
Number of subjects: 0
Study 28595249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue adhesives
Number of subjects: 71
Study 28595249 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 71
Study 25950180 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes group
Number of subjects: 41
Study 25950180 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance group
Number of subjects: 41
Study 25950180 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole population studied
Number of subjects: 41
Study 23587397 — intervention group
Group type: EXPERIMENTAL
Intervention: PF stents
Number of subjects: 989
Study 23587397 — intervention group
Group type: EXPERIMENTAL
Intervention: BD stents
Number of subjects: 989
Study 23587397 — intervention group
Group type: COMPARATOR
Intervention: PP stents
Number of subjects: 989
Study 21972615 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Guanyuan (CV 4) and Shenque (CV 8) in addition to standard treatment
Number of subjects: 100
Study 21972615 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment including Mifepristone, Rivanol, Misoprostol, uterine curettage, and Oxytocin
Number of subjects: 100
Study 19226886 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning needs identified among first-time CABG patients
Number of subjects: 0
Study 16738738 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day of zinc sulfate for four months)
Number of subjects: 58
Study 16738738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 58
Study 15327560 — intervention group
Group type: EXPERIMENTAL
Intervention: TriAc (0.1% in hydrophilic ointment) applied twice daily for 8 weeks
Number of subjects: 12
Study 15327560 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 8 weeks
Number of subjects: 12
Study 15327560 — intervention group
Group type: EXPERIMENTAL
Intervention: TriAc
Number of subjects: 12
Study 15327560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11241460 — intervention group
Group type: COMPARATOR
Intervention: 15 microg and placebo
Number of subjects: 815
Study 11241460 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg and 15 microg booster
Number of subjects: 815
Study 11241460 — intervention group
Group type: COMPARATOR
Intervention: 30 microg and placebo
Number of subjects: 815
Study 11241460 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg and 15 microg booster
Number of subjects: 815
Study 9285265 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressing the thought of weighing themselves
Number of subjects: 40
Study 9285265 — intervention group
Group type: COMPARATOR
Intervention: Expressing the thought of weighing themselves
Number of subjects: 40
Study 8275621 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg candoxatril
Number of subjects: 7
Study 8275621 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg candoxatril
Number of subjects: 7
Study 8275621 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg candoxatril
Number of subjects: 7
Study 8275621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3755916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation (10 infants)
Number of subjects: 17
Study 3755916 — intervention group
Group type: COMPARATOR
Intervention: Control (7 infants)
Number of subjects: 17
Study 30218372 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious intervention using Tavasol prayer and four recommended remembrances in 7 sessions
Number of subjects: 75
Study 30218372 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 28681988 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg/d
Number of subjects: 72
Study 26934454 — intervention group
Group type: COMPARATOR
Intervention: Biologics
Number of subjects: 1047
Study 26934454 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 1047
Study 26934454 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1047
Study 26934454 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 1047
Study 25336939 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing intervention with upper body resistance training (SE-UBR)
Number of subjects: 49
Study 25336939 — intervention group
Group type: COMPARATOR
Intervention: Health education with upper body resistance training (ED-UBR)
Number of subjects: 49
Study 25336939 — intervention group
Group type: COMPARATOR
Intervention: Health education with gentle chair exercises (ED-Chair)
Number of subjects: 49
Study 21225314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin plus 7.5 mg/m² rh-endostatin
Number of subjects: 66
Study 21225314 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin alone
Number of subjects: 66
Study 20546822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (M-M)
Number of subjects: 0
Study 20546822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond primer and Phenyl-P in bonding (M-P)
Number of subjects: 0
Study 20546822 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenyl-P in primer and Clearfil SE Bond bonding (P-M)
Number of subjects: 0
Study 20546822 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenyl-P in primer and bonding (P-P)
Number of subjects: 0
Study 20546822 — intervention group
Group type: EXPERIMENTAL
Intervention: All adhesive systems containing MDP
Number of subjects: 0
Study 20546822 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 18795912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass (LBM)
Number of subjects: 203
Study 18795912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 203
Study 18795912 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body bone mineral content (TBMC)
Number of subjects: 203
Study 18795912 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bone mineral density (TBMD)
Number of subjects: 203
Study 18795912 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight, height, total energy expenditure (TEE), physical activity level (PAL), father's educational level, and gender at age 15
Number of subjects: 203
Study 16248237 — intervention group
Group type: EXPERIMENTAL
Intervention: Shensong yangxin capsule (SYC)
Number of subjects: 221
Study 16248237 — intervention group
Group type: COMPARATOR
Intervention: Xinlvning tablet (Control)
Number of subjects: 221
Study 14676799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) followed by modified radical mastectomy
Number of subjects: 48
Study 14676799 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy (control group)
Number of subjects: 48
Study 10395121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of clodronate (400, 800, and 1600 mg) to healthy volunteers
Number of subjects: 33
Study 10395121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (800 and 1600 mg) twice daily for one week to cancer patients
Number of subjects: 33
Study 10395121 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine therapy with clodronate (400 mg thrice daily) in hospitalized cancer patients
Number of subjects: 33
Study 8718917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure treatment applied for 10 sec prior to injection
Number of subjects: 93
Study 8718917 — intervention group
Group type: COMPARATOR
Intervention: Standard injection with no pressure applied
Number of subjects: 93
Study 1725021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg
Number of subjects: 216
Study 1725021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 216
Study 1725021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 216
Study 1725021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 6093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 29
Study 6093487 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3/l alpha‐OHD3 (0.25 micrograms/day)
Number of subjects: 29
Study 6093487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31563095 — intervention group
Group type: EXPERIMENTAL
Intervention: WM load (n = 387)
Number of subjects: 821
Study 31563095 — intervention group
Group type: COMPARATOR
Intervention: No load (n = 434)
Number of subjects: 821
Study 29963921 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training (SLT)
Number of subjects: 41
Study 29963921 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional balance training (BLT)
Number of subjects: 41
Study 29963921 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 26152773 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish sauna (80℃) followed by cold-water immersion (12℃)
Number of subjects: 37
Study 26152773 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish sauna (80℃)
Number of subjects: 37
Study 26152773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (12℃)
Number of subjects: 37
Study 24508899 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day faropenem treatment
Number of subjects: 200